Home›Legal›CJC-1295 in Pennsylvania
CJC-1295 in Pennsylvania: Legal Status & Provider Guide (2026)
Quick Answer
CJC-1295 is a prescription substance in the United States. CJC-1295 is a synthetic GHRH analog with no FDA approval and no bulk compounding authorization. Federal compliance for compounding facilities is uncertain. Clinical use occurs in a regulatory gray area. In Pennsylvania, compounding is governed by the Pennsylvania State Board of Pharmacy (PSBP). Pennsylvania certified registered nurse practitioners (CRNPs) may prescribe compounded medications including peptides within a collaborative agreement. Physician assistants also require supervision agreements. Pennsylvania has moderately permissive telehealth rules, allowing prescribing after an appropriate telehealth evaluation. Pennsylvania prescribers must hold an active Pennsylvania license to prescribe to Pennsylvania residents.
Federal Legal Status
FDA Approval Status
Not FDA-approved. Not on the FDA 503A or 503B bulk substances lists. CJC-1295 (with or without DAC) is an unapproved research peptide.
Compounding Pharmacy Rules (Federal)
CJC-1295 is not on the FDA bulk substances list for 503A or 503B compounding. FDA has issued guidance indicating that unapproved peptides like CJC-1295 may not be lawfully compounded by facilities subject to FDA oversight. Providers offering it operate in a legally uncertain space under federal law.
Also Known As
Modified GRF (1–29) · Mod GRF 1–29 · DAC:GRF
Primary Research Areas
- Growth hormone release
- Anti-aging
- Body composition
- Muscle recovery
Pennsylvania Pharmacy Board & Compounding Rules
Compounding Overview
Pennsylvania's State Board of Pharmacy regulates compounding pharmacies with detailed sterile and non-sterile compounding standards. Pennsylvania has historically been home to several large-scale compounding operations. The state enforces USP 797 standards for sterile products and requires annual inspections for high-risk compounding. Pennsylvania is part of the northeastern corridor with significant demand from New York, New Jersey, and Delaware markets.
Notable Rules
- Pennsylvania requires pharmacies engaged in sterile compounding to have a separate license category.
- Annual inspections are required for pharmacies performing high-risk sterile compounding.
- Pennsylvania shares regulatory burden with the FDA for pharmacies also registered as 503B outsourcing facilities.
- Non-resident pharmacies shipping compounds into Pennsylvania must be registered with the PSBP.
- Pennsylvania and New York maintain some reciprocal licensing arrangements for pharmacy professionals.
Prescribing Requirements in Pennsylvania
Pennsylvania certified registered nurse practitioners (CRNPs) may prescribe compounded medications including peptides within a collaborative agreement. Physician assistants also require supervision agreements. Pennsylvania has moderately permissive telehealth rules, allowing prescribing after an appropriate telehealth evaluation. Pennsylvania prescribers must hold an active Pennsylvania license to prescribe to Pennsylvania residents.
About CJC-1295
CJC-1295 is a synthetic analog of GHRH designed for extended half-life through Drug Affinity Complex (DAC) technology. The DAC version binds to albumin in the bloodstream, extending its half-life significantly compared to sermorelin. It is often studied in combination with ipamorelin.
For more research information, mechanism of action, and provider availability, see the CJC-1295 research profile on PeptideBase.
Frequently Asked Questions
- What is the difference between CJC-1295 with DAC and without DAC?
- CJC-1295 with DAC binds to albumin and has a half-life of approximately 1–2 weeks, allowing less frequent dosing. CJC-1295 without DAC (also called Modified GRF 1-29) has a much shorter half-life of approximately 30 minutes, similar to sermorelin, and requires more frequent administration.
CJC-1295 Providers in Pennsylvania
No providers currently listed in Pennsylvania for CJC-1295. Browse the full directory to find providers offering CJC-1295.
Browse all CJC-1295 providers →CJC-1295 Legal Status in Other States
Pharmacy board rules and compounding regulations vary by state. Compare CJC-1295 legal status across other major markets:
Content review: This educational overview is prepared by the PeptideBase editorial team and reviewed for factual accuracy. Reviewer byline coming soon (gated on 4.4). Last updated: .